Pharmacy Bulletin

Pharmacy Bulletin

We share important prescription drug information to help you stay informed about updates concerning particular prescription medicines.

VativoRx Bottle update

Ticovac™ (tick-borne encephalitis vaccine) – New vaccine approval

Pfizer announced the FDA approval of Ticovac (tick-borne encephalitis vaccine), for active immunization to prevent tick-borne encephalitis (TBE). Ticovac is approved for use in individuals 1 year of age and older. August 13, 2021

Welireg™ (belzutifan) – New drug approval

The FDA announced the approval of Merck’s Welireg (belzutifan), for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. August 13, 2021

Durezol® (difluprednate) – First-time generic

Cipla announced the FDA approval of an AB-rated generic version of Alcon’s Durezol (difluprednate) ophthalmic emulsion. August 12, 2021

Keytruda® (pembrolizumab), Lenvima® (lenvatinib) – Expanded indication

The FDA approved Merck’s Keytruda (pembrolizumab), in combination with Eisai’s Lenvima (lenvatinib), for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). August 10, 2021

Mirena® (levonorgestrel-releasing intrauterine system) – Expanded indication

The FDA approved Bayer’s Mirena (levonorgestrel-releasing intrauterine system), for prevention of pregnancy for up to 7 years; replace after the end of the seventh year. August 11, 2021

Pfizer-BioNTech and Moderna COVID-19 vaccines – Emergency use authorization updated for additional dose for certain immunocompromised individuals

The FDA approved an amendment to the emergency use authorizations (EUAs) for both the Pfizer-BioNTech COVID-19 vaccine and the Moderna COVID-19 vaccine to allow for the use of an additional dose in certain immunocompromised individuals. August 12, 2021

Xywav® (calcium/magnesium/potassium/sodium oxybates) – New indication

Jazz Pharmaceuticals announced the FDA approval of Xywav (calcium/magnesium/potassium/sodium oxybates), for the treatment of idiopathic hypersomnia (IH) in adults. August 12, 2021

Pfizer – Expansion of recall of Chantix® (varenicline)

Pfizer announced an expansion of the voluntary consumer-level recall of Chantix (varenicline) tablets to include four additional lots due to the presence of a nitrosamine, N-nitroso-varenicline, above the Pfizer established acceptable daily intake (ADI) level. August 16, 2021

This information is shared with you from our partners at OptumRx.

If you’d like to receive the weekly bulletin by email, please let us know.